Litigation

Novartis To Pay $422.5M In Marketing, Kickbacks Case

PHILADELPHIA - (AP) Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials announced Thursday. The company agreed to plead guilty to distribution of a misbranded drug and pay. . . . Full version available to lexis.com subscribers.